MetaCap

CytomX Therapeutics (CTMX) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 119.7% versus a loss of 47.7%. Over five years, STTK leads with a -52.0% price change compared with -69.9% for CTMX. Shattuck Labs is the larger company by market cap ($454.2 million vs $442.5 million), about 1.0 times the size, while CytomX Therapeutics is growing revenue faster (-44.8% vs -82.5%).

CytomX Therapeutics converts more of its revenue into profit, with a net margin of -22.8% versus -4880.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTMX-47.68%STTK+119.70%
+314%+123%-69%
Nov 21, 20251 yearNov 20, 2026
CTMX-72.34%STTK-52.55%
+20%-40%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTMX versus STTK key metrics
MetricCTMXSTTK
Share price$2.03$4.46
Market cap$442.55M$454.22M
1-day change-0.98%-1.98%
YTD return-52.35%+22.19%
1-year return-47.68%+119.70%
5-year return-69.93%-51.99%
EPS (TTM)$-0.51$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$76.20M$1.00M
Revenue growth (YoY)-44.82%-82.52%
Net income (latest FY)$-17.37M$-48.81M
Operating margin-29.35%-5150.80%
Net margin-22.79%-4880.90%
52-week high$8.21$8.33
52-week low$1.87$1.93
Distance from 52-week high-75.27%-46.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+509.85%+245.29%
Average volume4.27M1.20M
Shares outstanding218.00M101.84M
Employees6940
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed CTMX by 167.4 percentage points over the past year.
  • CytomX Therapeutics is more profitable, keeping -22.8 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
  • CytomX Therapeutics grew revenue faster in its latest fiscal year (-44.82% vs -82.52%).

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

CTMX vs STTK FAQ

Which is bigger, CytomX Therapeutics or Shattuck Labs?

Shattuck Labs (STTK) is larger, with a market capitalization of $454.22M compared with $442.55M for CytomX Therapeutics (CTMX).

Which stock has performed better over the past year, CTMX or STTK?

STTK returned +119.70% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Are CytomX Therapeutics and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons